Edmond de Rothschild Holding’s 10x Genomics TXG Stock Holding History

Edmond de Rothschild Holding’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,699	Closed	-$920K	–	861
2021 Q2	$920K	Buy	4,699 +357	+8%	+$64.6K	0.02%	367
2021 Q1	$786K	Buy	+4,342	New	+$750K	0.02%	345

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

MCAV

Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edmond de Rothschild Holding's TXG Position: Q3 2021 in Review

Edmond de Rothschild Holding sold out of 10x Genomics (TXG) in Q3 2021, closing a stake of 4,699 shares — an estimated $920K sold.

Edmond de Rothschild Holding first reported a position in TXG in Q1 2021 and held it in 2 quarters. The position peaked at $920K in Q2 2021. 330 funds tracked by Wall St. Rank hold TXG as of Q3 2021.

Edmond de Rothschild Holding reported no remaining 10x Genomics position as of Q3 2021 after selling out during the quarter.
Edmond de Rothschild Holding sold 4,699 10x Genomics shares in Q3 2021, an estimated $920K.
Edmond de Rothschild Holding first reported a position in 10x Genomics in Q1 2021 and held it in 2 quarters.
Edmond de Rothschild Holding's 10x Genomics position peaked at $920K in Q2 2021.
330 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2021.

Based on Edmond de Rothschild Holding's 13F filing for Q3 2021, filed 12 Nov 2021.